El-Sayed: 0 AI regulation is 'existential'; seeks public control of health AI

For healthcare leaders, the debate is not abstract: AI algorithms already triage patients, read scans, and decide prior authorizations. El-Sayed's call for public board seats and a federal oversight body signals a future where health systems, insurers, and AI vendors face democratic control over clinical decision tools—and zero regulation is no longer an option.

Michigan Democratic Senate nominee Abdul El-Sayed declared on the "Head in the Office" podcast on June 12 that he would "actually take it a step further" than Bernie Sanders' proposal for public ownership of major artificial intelligence companies. El-Sayed not only endorsed public ownership but added that "we need some system of public control," arguing democracy must protect the public from AI's "existential risk" amid "no regulation." His examples of public control included public representation on corporate boards or a public oversight body over AI firms. The remarks were reported on Aug. 19 and 20, 2026 by Fox News and the New York Post.

“

Michigan Democratic Senate nominee Abdul El-Sayed declared on the "Head in the Office" podcast on June 12 that he would "actually take it a step further" than Bernie Sanders' proposal for public ownership of major artificial intelligence companies.

El-Sayed's comments land amid an intra-party fight over socialism. Rep. Jamie Raskin recently argued that young Americans who identify as socialists are not embracing government control of the means of production. El-Sayed's phrasing challenges that framing: he accepts "public ownership" and goes further by demanding "public control," a distinction that could mean not merely government expropriation but embedded democratic oversight in corporate governance. He warned that tech companies wield political power in Washington and "are trying to slip democracy," adding that leaders must "not be bought off by the AI industry itself."

At the federal level there is no comprehensive AI regulation. The AI industry has grown with voluntary commitments and a patchwork of state laws, while major companies consolidate data, compute, and talent. Sanders' public ownership model, while controversial, targets that concentration. El-Sayed's "step further" injects a governance mechanism: who gets a seat in decisions about deployment, safety, and pricing. For major AI companies, public board representation would be a structural shift, potentially reducing investor control and complicating rapid product cycles.

The distinction between public ownership and public control is more than rhetorical. Nationalization would shift equity and property rights; public control through board seats or an oversight body could preserve private ownership while imposing public-interest duties. That hybrid approach has precedents in regulated utilities, broadcast media, and some European corporate governance models, where worker or public representatives sit on boards. For healthcare, a similar model could require patient or government representatives on boards of companies whose AI influences clinical care, coverage decisions, or drug pricing. Such mandates would affect governance of electronic health record vendors, imaging AI startups, and payers using automated decision systems.